ÂÜÀòÂÒÂ×

Mike Narachi is a seasoned executive in the biotechnology and pharmaceutical industries, currently serving as President and CEO of CODA Biotherapeutics since August 2018, where the focus is on developing a Chemogenetic Gene Therapy Platform for intractable diseases. Narachi has also been a Board Member at the Biotechnology Innovation Organization since January 2012 and was previously the President and CEO of Orexigen Therapeutics from March 2009 to August 2018, overseeing the invention and global commercialization of Contrave, a weight loss therapeutic. Narachi's extensive experience includes serving on the Board of Directors for PhRMA from April 2013 to April 2017 and holding various leadership roles at Amgen from June 1984 to July 2004. Educational achievements include an MS and an MBA from the University of California institutions, with studies in genetics, molecular biology, philosophy, and business administration.